Komori
Earnings4521KAKEN PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Summary of Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)

For the fiscal year ended March 2026, net sales decreased 18.3% year on year, while operating income and ordinary income turned to losses. Net income attributable to owners of the parent also declined significantly. For the fiscal year ending March 2027, the Company forecasts net sales of ¥89,900 million and operating income of ¥7,900 million.

Worth reading
43Recurring
Scored from 3 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-18.3
% (year-on-year change in revenue)
Wording
Conditional
How definitive the wording is.

Results for this period

Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAP
Net Sales76,871¥ millionYear on year -18.3%Progress 85.5%
Operating profit-899¥ million
Ordinary income-206¥ million
Net income attributable to owners of the parent2,144¥ millionYear on year -84.6%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥56.57
Operating MarginCurrent fiscal year -1.2 % / Previous period 22.4 %
Financial position at period-end
Total assets178,217¥ million
of which net assets 147,619 ¥ millionEquity ratio 82.8%vs. prior year-end +3.9pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-11,079
Investment+315
Financials-8,841
Net change-19,605

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥50,705 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥89,900 million (YoY +17.0%)
Operating profit¥7,900 million
Ordinary income¥8,600 million
Profit attributable to owners of the parent¥6,500 million (YoY +203.1%)
Annual Dividend Forecast¥190 → ¥190(0.0%)
Payout ratioFiscal year ending March 2026 335.9 % / Forecast for the fiscal year ending March 2027 110.7 %
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End44,139,730
Treasury Shares at Period-End6,271,415
Results for this period
ItemDetails
Fiscal Period ClassificationFull year
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2025–31 March 2026
Net Sales¥76,871 million (YoY -18.3%)
Operating profit¥-899 million
Ordinary income¥-206 million
Profit attributable to owners of the parent¥2,144 million (YoY -84.6%)
Net income per share¥56.57
Operating MarginCurrent fiscal year -1.2 % / Previous period 22.4 %
Equity ratioEnd of the current fiscal period 82.8 / End of previous period 78.9
Total assets¥178,217 million
Net assets¥147,619 million
Cash flows from operating activities¥-11,079 million
Cash flows from investing activities¥315 million
Cash flows from financing activities¥-8,841 million
Cash and cash equivalents at end of period¥50,705 million
Full-year earnings forecastNet Sales ¥89,900 million (YoY +17.0%) / Operating profit ¥7,900 million / Ordinary income ¥8,600 million / Profit attributable to owners of the parent ¥6,500 million (YoY +203.1%)
Annual Dividend Forecast¥190 → ¥190(0.0%)
Payout ratioFiscal year ending March 2026 335.9 % / Forecast for the fiscal year ending March 2027 110.7 %
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End44,139,730
Treasury Shares at Period-End6,271,415
Items this document does not state (12)
Revision to Earnings ForecastShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionMaterial subsequent eventsFactors Behind Changes in Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The factors behind the year-on-year changes in results are not stated in the main text. The Company explains that its outlook for future results is based on information currently available and certain assumptions deemed reasonable, but actual results may differ significantly due to various factors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated) | KAKEN PHARMACEUTICAL CO.,LTD. (4521) timely disclosure | Komori